, Volume 31, Issue 6, pp 455–469

Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis

Issues to Consider
Practical Application

DOI: 10.1007/s40273-013-0063-4

Cite this article as:
Thompson, J.P., Abdolahi, A. & Noyes, K. PharmacoEconomics (2013) 31: 455. doi:10.1007/s40273-013-0063-4


Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, ‘real-world’ treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Community and Preventive Medicine, University of Rochester Medical CenterRochesterUSA